Bone Biologics Corp (BBLGW) — SEC Filings
Bone Biologics Corp (BBLGW) — 43 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 21 8-K, 7 SC 13G/A, 6 10-Q.
View Bone Biologics Corp on SEC EDGAR
Overview
Bone Biologics Corp (BBLGW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Bone Biologics Corp (BBLGW) reported no revenue for the nine months ended September 30, 2025, consistent with the prior year. The company incurred a net loss of $2.42 million for the nine months ended September 30, 2025, an improvement from the $2.59 million net loss in the same period of 2024. Rese
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 5 bearish, 38 neutral. The dominant filing sentiment for Bone Biologics Corp is neutral.
Filing Type Overview
Bone Biologics Corp (BBLGW) has filed 6 10-Q, 21 8-K, 2 S-1, 1 DEF 14A, 2 10-K, 7 SC 13G/A, 1 DEFA14A, 1 SC 13G, 2 S-1/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of BBLGW's 29 recent filings, 3 were flagged as high-risk, 17 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(2.42)M |
| EPS | $(2.51) |
| Debt-to-Equity | 0.05 |
| Cash Position | $6.05M |
| Operating Margin | N/A |
| Total Assets | $6.35M |
| Total Debt | $0.33M |
Key Executives
- Chief Executive Officer and President
- Jeffrey Frelick
- Alexander R. McClean, Esq.
- Steven M. Skolnick, Esq.
- Dr. Steven J. Lee
- Mr. David M. Dunshee
- Jagath Reddy
- Michael J. O'Leary
Industry Context
Bone Biologics operates in the highly competitive and capital-intensive biotechnology sector, focusing on regenerative medicine for bone repair. This industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes and eventual market adoption, facing competition from established players and other emerging biotech firms.
Top Tags
corporate-governance (7) · financials (5) · Medical Devices (4) · Public Offering (4) · regulatory-filing (4) · 8-K (3) · filing (3) · SEC Filing (3) · 10-Q (3) · quarterly-report (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | No revenue for the nine months ended September 30, 2025, consistent with prior year. |
| Net Loss | $(2.42)M | Net loss for the nine months ended September 30, 2025, an improvement from $(2.59)M in 2024. |
| Cash | $6.05M | Cash balance at September 30, 2025, up from $3.33M at December 31, 2024. |
| Accumulated Deficit | $87.45M | Total accumulated deficit as of September 30, 2025, indicating significant historical losses. |
| Estimated Operating Expenditures | $6.9M | Projected operating expenditures for the next twelve months, highlighting cash burn. |
| Net Proceeds from Public Offering | $4.35M | Capital raised on June 27, 2025, significantly boosting cash reserves. |
| Reverse Stock Split Ratio | 1-for-6 | Effected on June 10, 2025, impacting share count and per-share metrics. |
| Common Shares Outstanding | 1,795,260 | As of November 14, 2025, after the reverse stock split. |
| Loss per Share (Q3 2025) | $(0.37) | Loss per share for the three months ended September 30, 2025, post-split. |
| Loss per Share (YTD 2025) | $(2.51) | Loss per share for the nine months ended September 30, 2025, post-split. |
| SEC File Number | 001-40899 | Identifies the company's filing with the SEC |
| Fiscal Year End | 1231 | Indicates the end of the company's financial reporting year |
| Cash on hand | $6.64M | Increased from $3.33M at Dec 31, 2024, due to public offering. |
| Net Loss (6 months) | $1.76M | Increased from $1.65M in the prior year period. |
| Net proceeds from public offering | $4.35M | Raised on June 27, 2025, from common stock and warrants. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bone Biologics Corp (BBLGW)?
Bone Biologics Corp has 43 recent SEC filings from Jan 2024 to Nov 2025, including 21 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BBLGW filings?
Across 43 filings, the sentiment breakdown is: 5 bearish, 38 neutral. The dominant sentiment is neutral.
Where can I find Bone Biologics Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bone Biologics Corp (BBLGW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bone Biologics Corp?
Key financial highlights from Bone Biologics Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BBLGW?
The investment thesis for BBLGW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bone Biologics Corp?
Key executives identified across Bone Biologics Corp's filings include Chief Executive Officer and President, Jeffrey Frelick, Alexander R. McClean, Esq., Steven M. Skolnick, Esq., Dr. Steven J. Lee and 3 others.
What are the main risk factors for Bone Biologics Corp stock?
Of BBLGW's 29 assessed filings, 3 were flagged high-risk, 17 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Bone Biologics Corp?
Forward guidance and predictions for Bone Biologics Corp are extracted from SEC filings as they are enriched.